Real time capture of microscope video that is digitized, formatted and stored for AI and ML based use to enhance patient diagnosis.
Utilizing artificial intelligence in conjunction with the electrocardiogram to help clinicians identify cardiovascular disease more quickly, more accurately, and at a fraction of the cost. Real time capture of microscope video that is digitized, formatted and stored for AI and ML based use to enhance patient diagnosis. ViewsML uses a machine-learning model to predict biomarker expression in patient samples, both spatially and quantitatively. This reduces a 24+ hour process down to a few seconds, saving time and resources that can be redeployed elsewhere in the hospital or laboratory.
(Aug 2022- Nanopath announced that it has closed $10 million in Series A funding, co-led by Norwest Venture Partners and the Medtech Convergence Fund, a SV Health Investors venture fund, with participation from Gingerbread Capital and Green D Ventures.) Nanopath has developed a platform for rapid, point-of-care biomarker purification and characterization from a patient sample. Our technology is using advances in bioengineering and nanotechnology to reduce noise and improve signal in diagnostic systems. This allows for an integrated system that takes a complex patient sample, isolates key biomarkers, and analyses them without the need for lengthy clinical workflows. We believe that this new diagnostic paradigm has applications to a range of disease indications including bloodstream infections, cancer liquid biopsy, urinary tract infections, respiratory infections, and wound infections. It also finds use cases in fields of environmental monitoring and biosecurity.
Fungal bioproduction makes up 50% of the industrial enzymes market, a $10B market with a CAGR of 7.1% yearly. Fungal production of enzymes requires that large, dense cultures of cells be aerated properly. Dense cultures, however, become very viscous; stirring these cultures to provide oxygen can damage cells. Aethergen introduces mutations into fungi which convey morphology beneficial for fermentation processes, and lower oxygen consumption by half. This alleviates the need for a tradeoff between culture density and oxygen transfer. Aethergen can thus offer both enzyme manufacturers and strain improvement companies a more efficient process, lowering raw material costs and increasing margins.
Cancer patients, after the first diagnosis often ask, “how bad is my tumor and what should I do if it is bad?” In about half of all cancer patients, the first line of chemotherapy fails, disease recurs, and patients die. Episteme has succeeded in targeting a specific epigenetic signature of pancreatic cancer patients, which could potentially be reverted by epigenetic drugs making the tumors amenable to chemotherapy. Episteme invented a novel microarray-based platform technology called “ATAC-Array”. This proprietary technology avoids the time and cost of next-generation ATAC library sequencing – the only microarray that reads chromatin accessibility. No other test provides such a comprehensive, cost-effective and clinically useful epigenetic summary. Episteme offers a personalized theragnostic test utilizing ATAC-array, histopathology and immunohistochemistry, to predict chemotherapy response and stratifying cancer patients to epigenetic (reprograming) therapy for better outcome and better quality of life.